Program
vonafexor
Also written as “EYP001a”, “Vonafexor” and “Vonafexor low dose”.
Its studies are mostly in Hepatitis B, Chronic · Non-alcoholic Fatty Liver Disease · Renal Insufficiency, Chronic · Nephritis, Hereditary, led by Enyo Pharma.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Enyo Pharma | 110 open or running | phase 2since Jan 17, 2019 | Mar 31, 2017 | none ahead |
Also a collaborator on its studies: novotech-australia-pty-limited, synteract-inc, eurofins, parexel, cpr-pharma-services-pty-ltd-australia and pra-health-sciences.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 31, 2017First study: phase 1 study in HealthyFirst studyNCT03110276 · 80 enrolled
- Aug 31, 2017Phase 1 study in Hepatitis B, ChronicNCT03272009 · 73 enrolled · Australia, Netherlands, Poland and more
- Oct 20, 2017Phase 1 study in Hepatitis B, ChronicNCT03320616 · 11 enrolled · Netherlands
- Jan 29, 2018Phase 1 study in Hepatitis B, ChronicNCT03469583 · 16 enrolled · Australia
- Jan 17, 2019Phase 2 study in Non-alcoholic Fatty Liver DiseaseNCT03812029 · 120 enrolled · United States, Belgium, France and more
- Jun 4, 2019Phase 1 study in Non-alcoholic Fatty Liver DiseaseNCT03976687 · 16 enrolled · Australia
- Jul 26, 2019Phase 1 study in HealthyNCT04037618 · 6 enrolled · Netherlands
- Apr 23, 2020Phase 2 study in Hepatitis B, ChronicNCT04365933 · 20 enrolled · Hong Kong, Korea, Republic of, Taiwan
- Jul 6, 2020Phase 2 study in Hepatitis B, ChronicNCT04465916 · 26 enrolled · Australia, Hong Kong, Korea, Republic of and more
- May 14, 2024Phase 2 study in Nephritis, HereditaryNCT06425055 · 26 enrolled · United States, France, Spain
- Apr 7, 2025Phase 2 study in Renal Insufficiency, ChronicNCT06939816 · 10 enrolled · Germany
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 11 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06939816Renal Insufficiency, Chronic · Germany | 2 | Terminated | Dec 22, 2025 | 10 |
| NCT06425055Nephritis, Hereditary · United States, France, Spain | 2 | Completed | Sep 4, 2025 | 26 |
| NCT04465916Hepatitis B, Chronic · Australia, Hong Kong, Korea, Republic of and more | 2 | Terminated | Jun 17, 2021 | 26 |
| NCT04365933Hepatitis B, Chronic · Hong Kong, Korea, Republic of, Taiwan | 2 | Completed | Jun 16, 2021 | 20 |
| NCT04037618Healthy · Netherlands | 1 | Completed | Jul 27, 2019 | 6 |
| NCT03976687Non-alcoholic Fatty Liver Disease · Australia | 1 | Completed | May 25, 2020 | 16 |
| NCT03812029Non-alcoholic Fatty Liver Disease · United States, Belgium, France and more | 2 | Completed | Jun 16, 2021 | 120 |
| NCT03469583Hepatitis B, Chronic · Australia | 1 | Completed | Jun 20, 2018 | 16 |
| NCT03320616Hepatitis B, Chronic · Netherlands | 1 | Completed | Oct 12, 2017 | 11 |
| NCT03272009Hepatitis B, Chronic · Australia, Netherlands, Poland and more | 1 | Completed | Jul 30, 2018 | 73 |
| NCT03110276Healthy | 1 | Completed | Mar 2017 | 80 |
How it is read
Names in the registry
- “EYP001a”, 6 entries
- “Vonafexor”, 2 entries
- “Vonafexor low dose”, 1 entry
- “Vonafexor high dose”, 1 entry
- “[14C]-EYP001a”, 1 entry
Codes read as this program: EYP001A, EYP001.
Conditions, from the studies’ own filings
- Hepatitis B, Chronic, 5 studies
- Non-alcoholic Fatty Liver Disease, 2 studies
- Renal Insufficiency, Chronic, 1 study
- Nephritis, Hereditary, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.